Cell Lysis & Disruption Market
Get a free sample of this report
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Request Sectional Data
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Cell Lysis & Disruption Market size was valued USD 5.1 billion in 2023 and is expected to reach USD 10.9 billion by 2032 growing at a CAGR of 8.6% over the analysis period. High growth can be attributed to the expanding biopharmaceutical industry that relies on cell lysis and disruption techniques to produce therapeutic proteins, monoclonal antibodies, and vaccines.
Also, the growing interest in precision medicine and advancements in genomics research has further increased the demand for cell lysis and disruption technologies. Moreover, growing investments by several organizations, including government and private, towards the research and development related to biotechnological processes are further expected to drive the market. Thus, as the life sciences industry continues to evolve, the cell lysis and disruption market are expected to witness sustained growth.
Cell lysis and disruption refer to the process of breaking open or disrupting the cell membrane of biological cells, releasing the cellular contents. This is a crucial step in various biological and biochemical applications, such as protein purification & isolation, DNA or RNA isolation, and the production of cellular products.
Report Attribute | Details |
---|---|
Base Year: | 2023 |
Cell Lysis & Disruption Market size in 2023: | USD 5.1 Billion |
Forecast Period: | 2024 to 2032 |
Forecast Period 2023 - 2032 CAGR: | 8.6 |
2023 Value Projection: | USD 10.9 Billion |
Historical Data for: | 2018 to 2023 |
No of Pages: | 250 |
Tables, Charts & Figures: | 532 |
Segments Covered: | Technique, Product, Cell Type, Application, End-use, & Region |
Growth Drivers: |
|
Pitfalls Challenges: |
|
The COVID-19 pandemic had a positive impact on market progress. An increase in research and development activities for developing a vaccine for COVID-19 augmented the demand for technologies used for bioprocessing, including cell lysis & disruption. The severe respiratory effects of the virus created an urgent demand for innovative treatments, leading to further medication discoveries and favourable effects on the cell lysis industry.
However, the acquisition and maintenance costs associated with cutting-edge cell lysis equipment may be prohibitive for many laboratories and organizations, particularly those with limited budgets. This factor of high costs may pose a challenge for market growth.
Based on technique, the cell lysis and disruption market is segmented into reagent-based and physical disruption. The reagent-based segment is further categorised into detergent and enzymatic. The reagent-based segment is expected to lead the market, projecting revenue of USD 5.9 billion by 2032.
Based on product, the cell lysis & disruption market is classified into instruments and reagents & consumables. The reagents & consumables segment dominated the market in 2023 and is anticipated to grow at a CAGR of 8.4% between 2024 – 2032.
Based on cell type, the cell lysis & disruption market is classified into mammalian cells, microbial cells, and other cell types. The mammalian cells segment dominated the market accounting for the largest revenue of USD 2.4 billion in 2023.
Based on application, the cell lysis & disruption market is classified into protein isolation, nucleic acid isolation, and other applications. The protein isolation segment dominated the market accounting for 47.3% business share in 2023.
Based on end-use, the cell lysis and disruption market is classified into pharmaceutical and biotechnology companies, academic and research institutes, and other end-users. The pharmaceutical and biotechnology companies segment dominated the market in 2023.
In 2023, North America held a significant market share of 37.9% in the global cell lysis & disruption market and is anticipated to dominate the market throughout the forecast period.
The cell lysis and disruption industry is characterized by diverse players competing in the industry, leveraging their research capabilities and global presence. Strategic collaborations, product innovations, and regulatory compliance further strengthen their positions. Also, the market is characterized by ongoing technological advancements and a focus on developing safer and more effective products, further intensifying the competitive dynamics in the healthcare sector.
Prominent players operating in the cell lysis and disruption industry is as mentioned below:
By Technique, 2018 – 2032 (USD Million)
By Product, 2018 – 2032 (USD Million)
By Cell Type, 2018 – 2032 (USD Million)
By Application, 2018 – 2032 (USD Million)
By End-use, 2018 – 2032 (USD Million)
The above information is provided for the following regions and countries:
The global cell lysis & disruption industry size was valued USD 5.1 billion in 2023 and is expected to reach USD 10.9 billion by 2032, attributed to the expanding biopharmaceutical sector with focus on producing therapeutic proteins, monoclonal antibodies, and vaccines.
The reagent-based segment is expected to account for a revenue of USD 5.9 billion by 2032, these methods offer a cost-effective, simplified, and user-friendly approach, eliminating the need for complex equipment and specialized skills.
In 2023, North America held a significant market share of 37.9% and is anticipated to present lucrative opportunities over 2023-2032, backed by a robust infrastructure supporting cutting-edge R&D, a thriving biotechnology industry, and a well-established healthcare ecosystem.
Thermo Fisher Scientific, Inc., Merck KGaA, Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd., QIAGEN N.V., Danaher Corporation, Miltenyi Biotec, Claremont BioSolutions, LLC, and IDEX.